LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
The investigation concerns whether or not Nektar complied with the federal securities law. On October 1, 2018, a report was published by Plainview LLC alleged that Nektar’s plan to develop NKTR-214 into “a new universal cancer treatment” “has never worked in practice,” and further argued that Nektar’s choice to only disclose certain trial results represented “an unprecedented level of data opacity.” On this news, Nektar’s share price fell, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Nektar, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
